---
title: "Prelude Therapeutics regains compliance with Nasdaq $1.00 minimum bid price rule"
url: "https://aibio.space/news/prelude-therapeutics-regains-compliance-nasdaq-1-00-minimum-bid-price/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-09-19"
section: "Listings"
tickers: "NASDAQ:PRLD"
source: "https://www.sec.gov/Archives/edgar/data/1678660/000119312525208187/prld-20250918.htm"
summary: "Nasdaq told Prelude on September 18, 2025 that the bid-price matter is closed. The company had been out of compliance since a March 27, 2025 notice."
---

By the aibio.space news desk.

Sources

- [Prelude Therapeutics Incorporated 8-K (2025-09-19)](https://www.sec.gov/Archives/edgar/data/1678660/000119312525208187/prld-20250918.htm)

[PRLD](https://aibio.space/companies/prelude-therapeutics/)

2025-09-19

# Prelude Therapeutics regains compliance with Nasdaq $1.00 minimum bid price rule

Tickers [PRLD](https://aibio.space/companies/prelude-therapeutics/)

Nasdaq told Prelude on September 18, 2025 that the bid-price matter is closed. The company had been out of compliance since a March 27, 2025 notice.

## Key facts

- **Company**: Prelude Therapeutics Incorporated (NASDAQ: PRLD)

- **News type**: Listings

- **Primary source**: [Prelude Therapeutics Incorporated 8-K (2025-09-19)](https://www.sec.gov/Archives/edgar/data/1678660/000119312525208187/prld-20250918.htm)

*A stone federal courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Prelude Therapeutics Incorporated said Nasdaq has confirmed that the company is back in compliance with the exchange's minimum bid price requirement, closing a listing issue that began in March.

A bid-price deficiency means a company's shares have traded below the $1.00 per share minimum that Nasdaq sets for continued listing.

According to a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1678660/000119312525208187/prld-20250918.htm) filed on September 19, 2025, Prelude received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC on March 27, 2025. That letter said the company's common stock had failed to meet the $1.00 per share requirement. The company disclosed the notice on March 28, 2025.

On September 18, 2025, Prelude received a second letter from Nasdaq. It said the company has regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) and that "the matter is now closed."

Prelude's common stock trades on the Nasdaq Global Select Market under the symbol PRLD.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

PRLD

Prelude Therapeutics Incorporated

NASDAQ · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/prelude-therapeutics-regains-compliance-nasdaq-1-00-minimum-bid-price/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Prelude Therapeutics regains compliance with Nasdaq $1.00 minimum bid price rule", 2025-09-19, https://aibio.space/news/prelude-therapeutics-regains-compliance-nasdaq-1-00-minimum-bid-price/